These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22222382)

  • 1. Assessment of the relation between IVUS measurements and clinical outcome in elderly patients after sirolimus-eluting stent implantation for de novo coronary lesions.
    Du R; Zhang RY; Zhang Q; Shi YH; Hu J; Yang ZK; Ding FH; Zhang JS; Shen WF
    Int J Cardiovasc Imaging; 2012 Oct; 28(7):1653-62. PubMed ID: 22222382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of angiographic and intravascular ultrasound features on clinical outcome after sirolimus-eluting stent implantation for de-novo lesions in nondiabetic and type 2 diabetic patients.
    Du R; Zhang RY; Zhu ZB; Zhang Q; Hu J; Yang ZK; Yan ZJ; Lv AK; Ding FH; Zhang JS; Shen WF
    Coron Artery Dis; 2010 May; 21(3):175-81. PubMed ID: 20305549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
    Xu B; Dou K; Yang Y; Lv S; Wang L; Wang H; Li Z; Wang L; Chen Y; Huo Y; Li W; Kirtane AJ; Gao R
    EuroIntervention; 2012 Nov; 8(7):796-802. PubMed ID: 23171800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
    Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
    Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of neointimal hyperplasia and peri-stent vascular remodeling after implantation of everolimus-eluting versus sirolimus-eluting stents: intravascular ultrasound results from the EXCELLENT study.
    Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Gwon HC; Ahn T; Chae IH; Yoon JH; Kim HS; Jang Y;
    Int J Cardiovasc Imaging; 2013 Aug; 29(6):1229-36. PubMed ID: 23456359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.
    Meredith IT; Verheye S; Weissman NJ; Barragan P; Scott D; Valdés Chávarri M; West NE; Kelbæk H; Whitbourn R; Walters DL; Kubica J; Thuesen L; Masotti M; Banning A; Sjögren I; Stables RH; Allocco DJ; Dawkins KD
    EuroIntervention; 2013 Jul; 9(3):308-15. PubMed ID: 23872647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
    Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T
    J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
    Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intimal hyperplasia and vascular remodeling after everolimus-eluting and sirolimus-eluting stent implantation in diabetic patients: the randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound trial.
    Antonsen L; Maeng M; Thayssen P; Christiansen EH; Hansen KN; Kaltoft A; Hansen HS; Thuesen L; Lassen JF; Jensen LO
    Catheter Cardiovasc Interv; 2014 May; 83(6):864-72. PubMed ID: 23996918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
    Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison Between Optical Frequency Domain Imaging and Intravascular Ultrasound for Percutaneous Coronary Intervention Guidance in Biolimus A9-Eluting Stent Implantation: A Randomized MISTIC-1 Non-Inferiority Trial.
    Muramatsu T; Ozaki Y; Nanasato M; Ishikawa M; Nagasaka R; Ohota M; Hashimoto Y; Yoshiki Y; Takatsu H; Ito K; Kamiya H; Yoshida Y; Murohara T; Izawa H;
    Circ Cardiovasc Interv; 2020 Nov; 13(11):e009314. PubMed ID: 33106049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of preinterventional plaque composition and eccentricity on late-acquired incomplete stent apposition after sirolimus-eluting stent implantation: an intravascular ultrasound radiofrequency analysis.
    Sato T; Kameyama T; Noto T; Nozawa T; Inoue H
    Coron Artery Dis; 2012 Nov; 23(7):432-7. PubMed ID: 22936019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.